Name | 2-Hydroxy-5-methylpyridine |
Synonyms | AKOS BBS-00002970 5-Methyl-2-pyridinol 6-HYDROXY-3-PICOLINE 5-METHYL-2-PYRIDINOL 5-METHYL-PYRIDIN-2-OL 2-Pyridinol,5-methyl- 5-METHYLPYRIDINE-2-ONE 5-METHYL-2(1H)PYRIDONE 5-methyl-(1H)pyridinone 5-Methyl 2-(1H)pyridinone 5-methylpyridin-2(1H)-one 5-Methyl-2(1H)pypridinone 5-METHYL-2(1H)-PYRIDINONE 5-METHYL-2(1H)PYPRIDINONE 4-methylpyridin-2(1H)-one 5-Methyl-2-(1H)pyridinone 2-Hydroxy-5-methylpyridine 5-Methyl-2-hydroxypyridine |
CAS | 1003-68-5 91914-06-6 |
EINECS | 213-713-9 |
InChI | InChI=1/C6H7NO/c1-5-2-3-7-6(8)4-5/h2-4H,1H3,(H,7,8) |
InChIKey | SOHMZGMHXUQHGE-UHFFFAOYSA-N |
Molecular Formula | C6H7NO |
Molar Mass | 109.13 |
Density | 1.053±0.06 g/cm3(Predicted) |
Melting Point | 183-187 °C (lit.) |
Boling Point | 304.2±15.0 °C(Predicted) |
Flash Point | 170.6 °C |
Solubility | DMSO (Slightly), Ethanol (Slightly), Methanol (Slightly) |
Vapor Presure | 0mmHg at 25°C |
Appearance | White to brown powder or crystal |
Color | Pale Yellow to Light Yellow |
BRN | 107074 |
pKa | 12.43±0.10(Predicted) |
Storage Condition | Sealed in dry,Room Temperature |
Refractive Index | 1.551 |
MDL | MFCD03092888 |
Physical and Chemical Properties |
Hazard Symbols | Xn - Harmful |
Risk Codes | R22 - Harmful if swallowed R37/38 - Irritating to respiratory system and skin. R41 - Risk of serious damage to eyes R36/37/39 - |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36 - Wear suitable protective clothing. S37 - Wear suitable gloves. |
WGK Germany | 3 |
HS Code | 29333990 |
NIST chemical information | Information provided by: webbook.nist.gov (external link) |
Application | 2-hydroxy-5-methylpyridine is a pharmaceutical intermediate that can be used to prepare pirfenidone. Pirfenidone is a new pyridone compound with broad-spectrum anti-fibrosis effect, which is a white or light yellow crystalline powder. It can prevent and reverse the formation of fibrosis and scars; and the drug also has a good effect in renal interstitial fibrosis, liver fibrosis and other fibrotic diseases; at the same time, it is also used in kidney disease (focal segmental glomerulosclerosis), Hypertrophic cardiomyopathy, adult type I multiple neurofibroma, adolescent type I multiple neurofibroma and plexiform neurofibroma, diabetes with kidney disease, uterine leiomyoma and other phase II clinical studies have a wide range of applications. |
preparation | (1) mix 2-amino -5-methylpyridine, diazotization reagent and water evenly, cool to -4 ℃-3 ℃, add acidic solution for heat preservation reaction; After the reaction is complete, heat hydrolysis and cooling, and then adjust the pH to 6.5-7.5 with a mass fraction of 30% sodium hydroxide solution, the organic phase is extracted by the first solvent, dried and concentrated under reduced pressure to obtain 2-hydroxy-5-methylpyridine crude product;(2) A second solvent is added to the 2-hydroxy-5-methylpyridine crude product, heated and refluxed, cooled and crystallizated, pumped and dried to produce 2-hydroxy-5-methylpyridine pure product. |